Literature DB >> 11093794

Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB.

Z H Lee1, K Kwack, K K Kim, S H Lee, H H Kim.   

Abstract

Receptor activator of nuclear factor kappaB (RANK), a lately identified member of the tumor necrosis factor receptor superfamily, plays important roles both in osteoclastogenesis and in lymph node development. Previously, we and others showed that RANK could stimulate the activity of c-Jun N-terminal kinase (JNK). In this study, we investigated the mechanism by which RANK activates JNK. We found that N-terminal deletion mutants of tumor necrosis factor receptor-associated factor 2 and 6 were inhibitory to RANK activation of JNK. The JNK activation by RANK was also reduced by cotransfection of kinase-inactive mutants of apoptosis signal-regulating kinase 1, MAPK/ERK kinase kinase 1, and nuclear factor kappaB-inducing kinase. In addition, dominant negative mutants of Rac and Ras decreased the RANK stimulation of JNK activity. Furthermore, we determined whether the RANK engagement of JNK signaling pathways could lead to the activation of the activator protein 1 (AP-1) transcription factor, one of the potential downstream targets of activated JNK. RANK was found to activate AP-1 in a manner dependent on the signaling molecules involved in the JNK activation by this receptor. Furthermore, the activation of JNK and ERK, but not that of p38, appeared to be involved in the AP-1 activation by RANK. Thus, RANK may use both JNK and ERK pathways to signal to the AP-1 transcription factor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093794

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  Xtalk: a path-based approach for identifying crosstalk between signaling pathways.

Authors:  Allison N Tegge; Nicholas Sharp; T M Murali
Journal:  Bioinformatics       Date:  2015-09-23       Impact factor: 6.937

Review 2.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

3.  Tumor necrosis factor receptor-associated factor family protein 2 is a key mediator of the epidermal growth factor-induced ribosomal S6 kinase 2/cAMP-responsive element-binding protein/Fos protein signaling pathway.

Authors:  Cong Peng; Feng Zhu; Weihong Wen; Ke Yao; Shengqing Li; Tatyana Zykova; Kangdong Liu; Xiang Li; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  J Biol Chem       Date:  2012-06-08       Impact factor: 5.157

Review 4.  Role of RANKL and RANK in bone loss and arthritis.

Authors:  D Holstead Jones; Y-Y Kong; J M Penninger
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

5.  Exogenous regucalcin stimulates osteoclastogenesis and suppresses osteoblastogenesis through NF-κB activation.

Authors:  Masayoshi Yamaguchi; M Neale Weitzmann; Tomiyasu Murata
Journal:  Mol Cell Biochem       Date:  2011-08-14       Impact factor: 3.396

Review 6.  The TNF receptor superfamily: role in immune inflammation and bone formation.

Authors:  Xin Cheng; Masa Kinosaki; Ramachandran Murali; Mark I Greene
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 7.  Opioid administration following spinal cord injury: implications for pain and locomotor recovery.

Authors:  Sarah A Woller; Michelle A Hook
Journal:  Exp Neurol       Date:  2013-03-15       Impact factor: 5.330

Review 8.  Role of carotenoid β-cryptoxanthin in bone homeostasis.

Authors:  Masayoshi Yamaguchi
Journal:  J Biomed Sci       Date:  2012-04-02       Impact factor: 8.410

9.  Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL.

Authors:  Reimi Kawaida; Toshiaki Ohtsuka; Junichi Okutsu; Tohru Takahashi; Yuho Kadono; Hiromi Oda; Atsuhiko Hikita; Kozo Nakamura; Sakae Tanaka; Hidehiko Furukawa
Journal:  J Exp Med       Date:  2003-04-21       Impact factor: 14.307

10.  Inhibition of Osteoclastogenesis and Bone Resorption in vitro and in vivo by a prenylflavonoid xanthohumol from hops.

Authors:  Jing Li; Li Zeng; Juan Xie; Zhiying Yue; Huayun Deng; Xueyun Ma; Chunbing Zheng; Xiushan Wu; Jian Luo; Mingyao Liu
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.